Neurogene (NGNE) Other Non-Current Liabilities (2013 - 2026)
Neurogene's (NGNE) quarterly Other Non-Current Liabilities came in at $51000.0 in Q4 2025, down 92.9% YoY from $718000.0 in Q4 2024, and little changed on a QoQ basis from $51000.0 in Q3 2025.
Powered by 
Analysis
Neurogene (NGNE) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 10 years of Other Non-Current Liabilities data on file, last reported at $51000.0 in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 92.9% year-over-year to $51000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $51000.0 (down 92.9% YoY) and the FY2025 annual result came in at $51000.0, down 92.9% from the prior year.
- Other Non-Current Liabilities was little changed at $51000.0 in Q4 2025, from $51000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $718000.0 in Q4 2024 to a low of $51000.0 in Q2 2024.
- A 3-year average of $158888.9 and a median of $51000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 253.69% — and 2025, when it plunged 92.9%.
- Tracing NGNE's Other Non-Current Liabilities over 3 years: stood at $203000.0 in 2023, then surged by 253.69% to $718000.0 in 2024, then sank by 92.9% to $51000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $51000.0 (Q4 2025), $51000.0 (Q3 2025), and $51000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 407,000.00 |
| Mar 31, 2026 | 409,000.00 |
| Dec 31, 2025 | 428,000.00 |
| Sep 30, 2025 | 427,000.00 |
| Jun 30, 2025 | 738,000.00 |
| Mar 31, 2025 | 738,000.00 |
| Dec 31, 2024 | 718,000.00 |
| Sep 30, 2024 | 646,000.00 |
| Jun 30, 2024 | 717,000.00 |
| Mar 31, 2024 | 857,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Jun 30, 2019 | 2,000.00 |
| Mar 31, 2019 | 4,000.00 |
| Dec 31, 2018 | 319,000.00 |
| Sep 30, 2018 | 343,000.00 |
| Jun 30, 2018 | 401,000.00 |
| Mar 31, 2018 | 443,000.00 |
| Dec 31, 2017 | 486,000.00 |
| Sep 30, 2017 | 513,000.00 |
| Jun 30, 2017 | 548,000.00 |